An intriguing study investigated the mechanisms underlying the oncogenic role of m6A demethylase FTO in AML and found that a bio-imprinted nanoplatform targeting the FTO/m6A pathway can selectively target leukemic stem cells (LSCs) and induce ferroptosis (Cao et al., 2022), implying the clinical potential of targeting “m6A modification–ferroptosis axis” as a treatment strategy against AML. This evidence concerns the gene FTO and acute myeloid leukemia.